U.K. sets timetable for containers
This article was originally published in The Tan Sheet
Firms marketing nonprescription liquid cough and cold drugs in the U.K. must submit to health regulators by Feb. 12, 2010, plans for the child-resistant containers required by September 2010. The Medicines and Healthcare products Regulatory Agency Oct. 27 said it intends to approve changes by the end of March. MHRA imposed the regulation, which covers pharmacy-only and general-sale antihistamines, antitussives, expectorants and decongestants, following a comprehensive efficacy and safety review of children's cough/cold products. MHRA in February 2008 said children under 6 should not use OTC cough/cold products because of efficacy and safety concerns (1"The Tan Sheet" March 9, 2009)
You may also be interested in...
Manufacturers of pediatric cough/cold medicines sold in the U.K. have until March 2010 before the products must be sold behind the pharmacy counter, one of several measures to improve safe use
Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.